

South Carolina
Department of Health and Human Services
1801 Main Street
Columbia, South Carolina 29201-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
February 5, 2025
MINUTES

- I. Welcome and Call to order..... Dr. Edward Behling, MD
- Called to order at 4:01pm.

Freedom of Information Act/Americans with Disabilities Act Compliance Pledge – This body's official minutes will indicate that this meeting is in compliance with the Freedom of Information Act's mandate that the public be notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

- II. Roll Call Kimberly Bristow, RPh
- Committee members were encouraged to attend future meetings in person.

Committee Members Present:

Edward Behling, MD	Kelly Barth, DO	Duncan Norton, MD
Cheryl Hartvigsen, RPh	Divya Ahuja, MD	Philip Mubarak, MD
Katherine Lewis, MD	Garrett Whittle, PharmD	Oscar Lovelace, MD
Patricia Witherspoon, MD	Kimberly Rudd, MD	

SC DHHS Staff:

Sarah Hearn-Bailey, Esq.
Kevin Wessinger, MD
Kimberly Bristow, RPh
Brandie Crider, BSBA, CPhT
Tawanna Zeigler, MHSA, CPhT
Ashley Sirianni, DNP, FNP-BC

PRIME:

Lori Ash
Blake Cook, RPh
Manisa Bulsara, PharmD
Lisa Correll, PharmD
Alexis Jones, MHA, MA, CPhT

- III. Approval of Minutes from November 6, 2024..... P&T Committee
- The draft minutes from the previous P&T Committee meeting November 6, 2024, were emailed to the members for review prior to the meeting.
 - Duncan Norton, MD motioned to approve the previous P&T meeting minutes and Philip Mubarak, MD seconded the motion for approval. The minutes were approved unanimously.
- IV. State Updates Dr. Kevin Wessinger and Kim Bristow, RPh
- Dr. Wessinger gave updates on the single PDL (Preferred Drug List) launch fully on 1/1/2025. Dr. Wessinger also notified committee members that as of 1/2/2025 Cheryl Anderson, RPh has retired from the South Carolina Department of Health and Human Services. Kim Bristow will be Interim-Director until the director's position is filled.
 - Mrs. Bristow notified committee members that Xtampza® has become non rebated as of 1/1/2025 and the state has moved brand Oxycontin® to preferred on the sPDL. Due to the discontinuation of Levemir, Tresiba was added to the sPDL as preferred effective 2/1/2025. Effective 3/1/2025, Baclofen oral solution 5mg/5mL and 10mg/5mL will no longer require a prior authorization for patients 12 years of age or younger. Baclofen 25mg/5mL suspension will still require a prior authorization.
- V. Review of P&T Bylaws..... Dr. Edward Behling, MD
- Dr. Behling stated the P&T Committee Bylaws reflects the input that has been given by committee members. There were no questions or concerns about edits. Mrs. Bristow informed committee members that attestation forms will be sent out to members who were not in person to be completed and returned.
 - Duncan Norton, MD motioned for P&T committee bylaws to be approved, and Philip Mubarak, MD seconded the motion for approval. This change was approved unanimously.
- VI. Committee Elections..... Dr. Edward Behling, MD
- Nominations were opened to the committee for the role of Vice-Chair-Dr. Ahuja was nominated. The floor was open for additional nominations - no others were provided/no opposition. Dr Ahuja accepted the nomination.
 - Duncan Norton, MD motioned for approval of Dr. Ahuja to be vice chairperson, and Philip Mubarak, MD seconded the motion for approval.
- VII. Pharma Updates..... Manisa Bulsara, PharmD
- Dr. Bulsara informed the committee that the State plans to continue utilizing the randomization process for meeting requests in 2025. There will be one

40-minute meeting per entity per year. Any questions or concerns can be directed to scpharma@primetherapeutics.com.

VIII. New Drugs to Market..... Manisa Bulsara, PharmD

- Erzofri[®]™ (paliperidone palmitate)
- Vafseo[®] (vadadustat)
- Yorvipath[®] (palopegteriparatide)
- Ebglyss[™] (lebrikizumab-lbkz)
- Miplyffa[™] (arimoclomol citrate)
- Aqneursa[™] (levacetylleucine)
- Cobenfy[™] (xanomeline and trospium chloride)
- Zituvimet/XR[™] (sitagliptin and metformin)
- Opipza[™] (aripiprazole) oral film
- Attruby[™] (acoramidis HCl)
- Wezlana[™] (ustekinumab-auub)

IX. Classes for Review..... Manisa Bulsara, PharmD

- Influenza Anti-Viral
 - No speaker/presenter.
 - Adding oseltamivir phosphate (Tamiflu[®]) and rimantadine (Flumadine[®]) as preferred.
 - Adding amantadine (Symmetrel[®]), Flumadine[®], Relenza Diskhaler[®], Tamiflu[®], and Xofluza[®] as non-preferred. Non-preferred medications will require a trial and failure of only one preferred product.
 - After several points of discussion, products within this class will remain open. Class may be revisited at the next P&T meeting.
- Penicillin, Cephalosporins and Related Category
 - No speaker/presenter.
 - Adding Amoxicillin (Amoxil[®], Trimox[®]), amoxicillin-clavulanate (Augmentin[®]/XR), Ampicillin, cefaclor (Ceclor[®]), cefadroxil capsule/suspension (Duricef[®]), cefdinir (Omnicef[®]), cefixime (Suprax[®]), cefpodoxime (Vantin[®]), cefprozil (Cefzil[®]), cefuroxime (Ceftin[®]), cephalixin (Keflex[®]), Dicloxacillin, Penicillin V as preferred.
 - Adding Augmentin[®]/XR, Cefadroxil tablet (Duricef[®]), Cefaclor ER (Ceclor[®] CD), and Suprax[®] as non-preferred.
 - Divya Ahuja, MD motioned for this to be approved, and Cheryl Hartvigsen, RPh seconded the motion for approval. This change was approved unanimously.

X. Drug Classes for Re-Review Manisa Bulsara, PharmD

- Hepatitis B
 - No speaker/presenter.
 - Adding Vemlidy®, Tenofovir disoproxil fumarate (Viread®), and Viread® as preferred.
 - Duncan Norton, MD motioned for this to be approved, and Philip Mubarak, MD seconded the motion for approval. This change was approved unanimously.
- Ophthalmic Anti-Inflammatories
 - No speaker/presenter.
 - Adding dexamethasone (Decadron®, Maxidex®), Durezol®, Flarex®, Fluorometholone (FML®), Maxidex®, Pred Mild®, and prednisolone acetate (generic for Pred Forte®) as preferred.
 - Adding difluprednate (Durezol®), FML® Forte/Liquifilm, Inveltys®, Lotemax®, loteprednol (Lotemax®), Pred Forte®, and prednisolone sodium phosphate (Inflamase Forte®) as non-preferred.
 - Philip Mubarak, MD motioned for this change to be accepted and Duncan Norton, MD seconded the motion for approval. This change was approved unanimously.

XI. Brand to Generic Switch Manisa Bulsara, PharmD

- Effective 3/1/2025 Lacosamide (Vimpat®) will be preferred. Brand Vimpat® will move to non-preferred. Clinical criteria not required for generic lacosamide.
- Effective 4/1/2025 Aprepitant (Emend®) will be preferred. Brand Emend® will move to non-preferred. Tadalafil (Adcirca®) will be preferred. Brand Adcirca® will move to non-preferred. Lubiprostone (Amitiza®) will be preferred. Brand Amitiza® will move to non-preferred. Vancomycin (Firvanq®) will be preferred. Brand Firvanq® will move to non-preferred. Moxifloxacin (Vigamox®) will be preferred. Brand Vigamox® will move to non-preferred.

XI. PDL (Preferred Drug List) Housekeeping..... Manisa Bulsara, PharmD

- Pharma mailbox: scpharma@primetherapeutics.com
- On 1/1/2025 Oxycontin® was moved to preferred.
- On 2/1/2025 Tresiba® was moved to preferred.
- Effective 3/1/2025 Baclofen 5mg/5mL and 10mg/5mL will no longer require a prior authorization for 12 years or younger.
- Effective 4/1/2025 Brand and Generic switches and removal of prior authorization for Clobazam.
- All other category changes discussed will be effective 7/1/2025.

- As stated on the previous P&T meeting, the state will be adding Difidid as preferred to sPDL effective 4/1/2025. Difidid will be monitored for utilization and claims.
- The hypereosinophilic syndrome category will not be included on the PDL as a separate category (Injectable Immunomodulators). Currently only one medication within this class, Nucala, carries this indication. Requests for Nucala for hypereosinophilic syndrome will continue to be evaluated via a prior authorization.

XII. Next P&T Meeting will be held on Wednesday, May 7, 2025, at 4pm.

- All P&T Committee members are encouraged to attend in person.

XII. Open Discussion

There was a general comment posed by Dr Behling regarding the migration to single PDL- any items of concern/of note. Dr Wessinger noted that overall, the move to single PDL has been a cost savings for the State. With the continuity period ending 1/1/2025, there has been outreach regarding several branded products/ availability/ access. Dr. Mubarak voiced concern regarding children on established ADHD medications and prior authorization processes. Dr. Ahuja requested a state contact/ resource for 340b specific questions- the State has this as a take-away item.

XIII. Adjournment

- Meeting adjourned at 5:22pm.